Can progression of autosomal dominant or autosomal recessive polycystic kidney disease be prevented?

Seminars in Nephrology

Volumn 21, Issue 5, 2001, Pages 430-440

  Davis, Ira D ^a   Dell, Katherine MacRae ^a   Sweeney, William E ^a   Avner, Ellis D ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; CILAZAPRIL; CITRATE POTASSIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; KETOCONAZOLE; LOSARTAN; MEVINOLIN; PREDNISOLONE; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; UNINDEXED DRUG;

AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL RECESSIVE DISORDER; DIET THERAPY; DISEASE COURSE; GENE THERAPY; HUMAN; HYPERTENSION; KIDNEY CYST; KIDNEY INJURY; KIDNEY PARENCHYMA; KIDNEY POLYCYSTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; REVIEW;

EID: 0034844158     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1053/snep.2001.24937     Document Type: Review

References (113)

1. US Renal Data System: Excerpts from the USRDS 2000 Annual Data Report: Atlas of End-Stage Renal Disease in the United States
2. The European PKD1-PKD2 study group: Comparison of phenotypes of polycystic kidney diseases types 1 and 2
3. Factors affecting the progression of renal disease in autosomal-dominant polycystic disease
4. Course of autosomal recessive polycystic kidney disease (ARPKD) in siblings: A clinical comparison of 20 sibships
5. Autosomal recessive polycystic kidney disease in 115 children: Clinical presentation, course and influence of gender
6. Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats
7. The reninangiotensin-aldosterone system and autosomal dominant polycystic kidney disease
8. Hypertension in polycystic kidney disease
9. Progression of renal failure in patients with renal disease of diverse etiolog on protein-restricted diet
10. Renal structure and hypertension in autosomal dominant polycystic kidney disease
11. Causes of death in autosomal dominant polycystic kidney disease
12. Angiography in polycystic disease of the kidneys
13. The anatomy of the renin-secreting cell in adult polycystic kidney disease
14. Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease
15. Effects of angiotensin converting enzyme inhibition in adult polycystic kidney disease
16. Reduction in albuminuria predicts diminished progression in diabetic nephropathy
17. Effect of angiotensin-converting-enzyme inhibitor benaazepril on the progression of chronic renal insufficiency
18. Lowering of arterial blood pressure limits glomerular sclerosis in rats with renal ablation and in experimental diabetes
19. Pathophysiology of progressive nephropathies
20. Overt proteinuria and microalbuminemia in autosomal dominant polycystic kidney disease
21. Influence of the ACE gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease
22. The angiotension-converting enzyme genotype and microalbuminuria in autosomal dominant polycystic kidney disease
23. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease
24. Identification of patients with autosomal dominant polycystic kidney disease at highest risk of end-stage renal disease
25. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease
26. Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury
27. Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in Han:SPRD rats
28. Cilazapril delays progression of hypertension and uremia in rat polycystic kidney disease
29. Dietary treatment in renal failure
30. Diet in chronic uremia
31. Altered glomerular permselectivity and progressive sclerosis following extreme ablation of renal mass
32. Effects of low-protein diet on experimental diabetic nephropathy
33. Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy
34. Restriction of dietary protein and progression of renal failure in diabetic nephropathy
35. Selective effect of low protein diets in chronic renal diseases
36. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease
37. Prospective randomised trial of early dietary protein restriction in chronic renal failure
38. The progression of renal disease
39. Retardation of the progression of renal insufficiency in patients treated with low-protein diets
40. Low-protein diet supplemented by keto acids in chronic renal failure: A prospective controlled study
41. Protein-restricted diets in chronic renal failure: A four year followup shows limited indications
42. Prospective randomized, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency
43. Effects of dietary protein restriction and oil type on the early progression of murine polycystic kidney disease
44. Early dietary protein restriction slows disease progression and lengthens survival in mice with polycystic kidney disease
45. Dietary soy protein effects on inherited polycystic kidney disease are influenced by gender and protein level
46. Amelioration of polycystic kidney disease by modification of dietary protein intake in the rat
47. Modification of disease progression in rats with inherited polycystic kidney disease
48. Renal remodeling in dietary protein modified rat polycystic kidney disease
49. Modern applications for an ancient bean: Soybeans and the prevention and treatment of chronic disease
50. Metabolic consequences of differing protein diets in experimental renal disease
51. Diet and suitability of the male Fischer 344 rat as a model for aging research
52. The modification of the arachidonic acid cascade by n-3 fatty acids
53. Effects of flaxseed and flax oil diets in a rat 5/6 renal ablation model
54. Abrogation of MRL/lpr lupus nephritis by dietary flaxseed
55. Fish oil therapy for IgA nephropathy: Efficacy and interstudy variability
56. A central role for protein kinase C overactivity in diabetic glomerulosclerosis: Implications for prevention of with antioxidants, fish oil, and ACE inhibitors
57. Cytokines in fluids form polycystic kidneys
58. Soy protein modification of rat polycystic kidney disease
59. Modification of polycystic kidney disease and fatty acid status by soy protein diet
60. Effect of dietary soy protein and genistein on disease progression in mice with polycystic kidney disease
61. Flaxseed ameliorates interstitial nephritis in rat polycystic kidney disease
62. Aggravation of polycystic kidney disease in Han:SPRD rats by buthionine sulfoximine
63. Targeted disruption of Bcl-2a b in mice: Occurrence of gray hair, polycystic kidney disease, and lymphocytopenia
64. Renal concentration of C-tocopherol: Dependence of gender and lack of effect on polycystic kidney disease in han:sprd rats
65. Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis
66. Lovastatin inhibits proliferation of rat mesangial cells
67. Effect of lovastatin on the development of polycystic kidney disease in the han:sprd rat
68. Lovastatin inhibits cAMP- and calcium-stimulated chloride secretion by T84 cells
69. Weighted least squares regression analysis of factors contributing to progression of chronic renal failure
70. Effect of ketoconazole plus low-dose prednisone on progression of chronic renal failure
71. New insights into the molecular pathophysiology of polycystic kidney disease
72. Taxol inhibits progression of congenital polycystic kidney disease
73. Microtubule active taxanes inhibit polycystic kidney disease progression in cpk mice
74. The effect of paclitaxel on the progression of polycystic kidney disease in rodents
75. Efficacy of taxol in the orpk mouse model of polycystic kidney disease
76. Renal cystic disease and ammoniagenesis in han:sprd rats
77. Potassium citrate/citric acid intake improves renal function in rats with polycystic kidney disease
78. Effects of sodium bicarbonate and ammonium chloride administration on the polycystic kidney disease of pcy/pcy mice
79. Opposite response to NaHCO3 administration in pck and Han:SPRD rats
80. Contributions of mononuclear leukocytes to the progression of experimental focal glomerular sclerosis
81. Methyl-prednisolone retards the progression of inherited polycystic kidney disease in rodents
82. Definition of androgens and protein anabolic steroids
83. Epidermal growth factor receptor expression is abnormal in murine polycystic kidney
84. Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD
85. Expression of differentiation antigens and growth-related genes in normal kidney, autosomal dominant polycystic kidney disease, and renal cell carcinoma
86. Functional activity of epidermal growth factor receptors in autosomal recessive polycystic kidney disease
87. Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease
88. A mutation in the epidermal growth factor receptor in waved-2 mice has a profound effect on receptor biochemistry that results in impaired lactation
89. Anticancer drug targets: Growth factors and growth factor signalling
90. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor
91. CL-387,785: An irreversible inhibitor of epidermal growth factor receptor tyrosine kinase with in vivo activity
92. EGF receptor
93. Binding specificities and affinities of egf domains for ErbB receptors
94. Expression of transforming growth factor alpha and epidermal growth factor receptor in adult polycystic kidney disease
95. BPK cyst fluid contains EGF and TGF-α like peptides which are mitogenic and phosphorylate apical EGFR
96. Renal cysts in transgenic mice expressing transforming growth factor-alpha
97. Renal dysfunction but not cystic change is ameliorated by neonatal EGF in bpk mice
98. A novel inhibitor of TNF-alpha converting enzyme ameliorates polycystic kidney disease
99. Cyst formation and growth in autosomal dominant polcystic kidney disease
100. Renal cysts in pediatric patients: A classification and overview
101. Correction of renal tubular acidosis in carbonic anhydrase II-deficient mice with gene therapy
102. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells
103. Chloride and fluid secretion in polycystic kidney disease
104. Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease
105. Role of CFTR in autosomal recessive polycystic kidney disease
106. Evidence for a potent lipid secretagogue in the cyst fluids of patients with autosomal dominant polycystic kidney disease
107. Abnormalities in extracellular matrix regulation in autosomal dominant polycystic kidney disease
108. Acidic FGF regulation of hyperproliferation of fibroblasts in human autosomal dominant polycystic kidney disease
109. Elevation of serum levels of metalloproteinase-1, tissue inhibitor of metalloproteinase-1 and type IV collagen, and plasma levels of metalloproteinase- 9 in polycystic kidney disease
110. Matrix metalloproteinases and TIMPS in cultured C57BL/6J-cpk kidney tubules
111. Matrix metalloproteinase-2 in a murine model of infantile-type polycystic kidney disease
112. Synthetic inhibitor of matrix metalloproteases decreases tumor growth and metastases in a syngeneic model of rat prostate cancer in vivo
113. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies